FDA recalls Baxter IV solutions; Drug delivery company plunges on Wall Street following bad trial results;

> Baxter ($BAX) initiated a voluntary recall of some of of its IV solutions due to the potential presence of particulate matter. More

> Alzheon believes it can succeed where many others have failed due to an oral, reformulated Alzheimer's candidate. It's a prodrug, meaning the critical ingredient is delivered in an inactive state and becomes activated once in the body. To get the treatment to Phase III, the company received $10 million in a Series A financing. The candidate will only be tested on patients with a certain gene. More

> Eye drug delivery company Ocular Therapeutix saw its stock plunge 30% last week on the heels of disappointing clinical trial results. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.